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Abstract
Introduction. Caffeine is indicated in the treatment of
migraine headaches, as well as neonatal apnea and brady-
cardia syndrome. In mild poisoning, the most prevalent
symptoms are nausea, vomiting, diarrhea, tremor, anxiety
and headache. In more severe cases, symptoms consist of
heart rythym abnormalities, myocardial infarction and sei-
zures. Due to its common lipolytic effect, caffeine is used
in mesotherapy, usually in combination with drugs of
similar effect. We presented a patient with acute iatrogenic
caffeine poisoning. Case report. A 51-year-old woman,
with preexisting hypertension and hypertensive cardiomy-
opathy was subjected to cosmetic treatment in order to
remove fat by intradermal caffeine injections. During the
treatment the patient felt sickness, an urge to vomit, and a
pronounced deterioration of general condition. Upon ex-
amination, the patient exhibited somnolence, hypotension
and nonsustained ventricular tachycardia, which was suffi-
cient enough evidence for further hospitalization. On ad-
mission to the intensive care unit the patient was anxious
with increased heart rate, normotensive, with cold, damp
skin, and visible traces of injection sites with surrounding
hematomas on the anterior abdominal wall. Paroxysmal
supraventricular tachycardia (PSVT) on electrocardio-
graphic monitoring was found. The laboratory analysis
determined a lowered potassium level of 2.1 mmol/L
(normal range 3,5 – 5.2 mmol/L), and a toxicological
analysis (liquid chromatography with ultraviolet detection)
proved a toxic concentration of caffeine in plasma – 85.03
mg/L (toxic concentration over 25 mg/L). On application
of intensive therapy, antiarrhythmics, and substitution of
potassium, as well as both symptomatic and supportive
therapy, there was a significant recovery. The patient was
discharged without any sequele within four days. Conclu-
sion. A presented rare iatrogenic acute caffeine poisoning
occured due to massive absorption of caffeine from the
subcutaneous adipose tissue into the circulation when in-
jected directly into the tiny blood vessels, as evidenced by
hematoma formation. Poisoning manifestations were reg-
istered in gastrointestinal, CNS (anxiety, somnolence) and
cardiovascular (hypotension, ventricular tachycardia and
nonsustained PSVT) system. In this era of mesotherapeu-
tic treatment promotion, one should keep in mind toxic
prevention, with application being carried out exclusively
in a specialized institution
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Apstrakt
Uvod. Kofein se primenjuje u leÿenju migrenozne glavo-
bolje, a kod dece u leÿenju neonatalne apneje i sindroma
bradikardije. Kod lakših trovanja kofeinom najÿešýe se ja-
vljaju muÿnina, povraýanje, dijareja, tremor, anksioznost i
glavobolja, a kod teških trovanja poremeýaji srÿanog ritma,
infarkt miokarda i konvulzije. Zbog poznatog lipolitiÿkog
efekta kofein se koristi i u mezoterapiji, obiÿno u kombi-
naciji sa supstancama koje sliÿno deluju. Prikaz bolesni-
ka. Bolesnica, stara 51 godinu, sa postojeýom hipertenzi-
jom i hipertenzivnom kardiomiopatijom, bila je podvrg-
nuta estetskom tretmanu uklanjanja masnih naslaga putem
intradermalnog ubrizgavanja kofeina. Tokom tretmana
osetila je muÿninu, nagon za povraýanjem i izrazito pogor-
šanje opšteg stanja. Pri prvom pregledu utvrĀeni su som-
nolencija i hipotenzija, a u EKG ventrikularna tahikardija
nonsustained, zbog ÿega je upuýena na bolniÿko leÿenje. Pri
prijemu u jedinicu intenzivne nege bolesnica je bila anksi-
ozna, tahikardiÿna, normotenzivna, sa hladnom i vlažnom
kožom, a na trbuhu su bili vidljivi tragovi uboda sa okol-
nim hematomima. Elektrokardiografskom kontrolom regi-Strana 708  VOJNOSANITETSKI PREGLED Volumen 69, Broj 8
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strovana je paroksizmalna supraventrikularna tahikardije
(PSVT). Laboratorijskim analizama utvrĀen je snižen nivo
kalijuma – 2,1 mmol/L (3,5–5,2 mmol/L), a toksikološkim
analizama (teÿna hromatografija sa ultravioletnim detekto-
rom) dokazan je kofein u toksiÿnoj koncentraciji – 85,03
mg/L (toksiÿna koncentracija preko 20 mg/L). Na prime-
njenu intenzivnu terapiju, antiaritmike i supstituciju kali-
juma, simptomatsku i suportivnu terapiju, došlo je do opo-
ravka, te je ÿetvrtog dana bolesnica otpuštena bez posledi-
ca. Zakljuÿak. Opisano retko jatrogeno akutno trovanje
kofeinom nastalo je atipiÿno – zbog masivne resorpcije
kofeina iz potkožnog adipoznog tkiva u cirkulaciju. Ubriz-
gavanje direktno u sitne krvne sudove potvrĀeno je prisu-
stvom hematoma. Manifestacije trovanja bile su prisutne u
gastrointestinalnom, centralnom nervnom (anksioznost,
somnolencija) i kardiovaskularnom (hipotenzija, ventriku-
larna tahikardija nonsustained i PSVT) sistemu. U eri pro-
mocije mezoterapijskih estetskih tretmana treba imati na
umu takvu opasnost i estetske intervencije sprovoditi is-
kljuÿivo u visokospecijalizovanim ustanovama.
Kljuÿne reÿi:
kofein; trovanje; kozmetiÿke tehnike;
rizik, procena.
Introduction
The biochemical structure of caffeine is 1,3,7-
trimethylxanthine. This compound belongs to a class of
theophyllines with the chemical structure of 1,3-
dimethylxanthine and theobromine, 3,7-dimethylxantine.
Being an ingredient that is found in coffee, tea, cocoa and
various drinks, caffeine is used routinely. The therapeutic use
of caffeine in adults is an adjuvant therapy in combined an-
algesics for the treatment of migraine headaches, in children
for the treatment of neonatal apnea, and in bradycardia syn-
drome. Caffeine, theophylline and theobromine belong to the
group of methylxanthines, which cause the release of en-
dogenous catecholamines, leading to the stimulation of adre-
nergic receptors. They are structural analogues of adenosine
and pharmacologically function as adenosine antagonists. In
higher doses, methylxanthines inhibit phosphodiesterase, the
enzyme responsible for degradation of intracellular cyclic
adenosine monophosphate (cAMP). The increase in cAMP
leads to the clinical effects of adrenergic stimulation, muscle
relaxation, stimulation of the myocardium, peripheral vaso-
dilatation, stimulation of the respiratory center and the exci-
tation of the central nervous system (CNS). Caffeine is
bioavailable after oral, intravenous, subcutaneous, intramus-
cular and rectal application 
1, 2. Caffeine metabolism occurs
via hepatic cytochrome P450 oxidase, the main processes in-
cluding demethlylation and hydroxylation, with metabolic
by-products (3,7-dimethylxanthine) teobromin, and (1,3-
dimethyxsanthine) theophylline. For this reason, in patients
with caffeine poisoning, serum concentrations of theophyl-
line must be determined 
1, 3. Methylxanthines have a positive
chronotropic and inotropic effect on the myocardium, lead-
ing to supraventricular tachycardia, atrial fibrillation, atrial
flutter, multifocal atrial tachycardia, ventricular tachycardia
and ventricular fibrillation. Electrolyte imbalances may be a
factor in enhancing the development of arrhythmias. Caf-
feine and theophylline stimulate the respiratory center and
increase respiratory rate (frequency of breathing), and there-
fore are used to treat sleep neonatal apnea syndromes. Ef-
fects on the CNS are manifested as headache, anxiety, agita-
tion, insomnia, tremor, irritability, hallucinations and sei-
zures. The effects exhibited on the musculoskeletal system
result in an increase of intracellular calcium, muscle excita-
tion, tremors, fasciculations and rhabdomyolysis 
1. The most
common and mild clinical effects of caffeine toxicity are si-
nus tachycardia, hypertension, nausea, vomiting, anxiety,
CNS agitation and palpitations. Severe clinical effects, fortu-
nately less common, are seizure, dysrhythmias, myocardial
infarction, hypertensive crisis, hyperthermia and delirium 
3.
Treatment of patients with severe caffeine intoxication
includes admission to the intensive care unit, electrocardio-
graphic (ECG) monitoring, intensive therapy with isotonic
solutions, as well as other forms of symptomatic and suppor-
tive therapy. In methylxantine severe poisoning, charcoal
and hemodialysis are used in order to counteract caffeine’s
resistance. Indications for hemoperfusion through activated
charcoal and hemodialysis are: serum levels of caffeine
which are greater than 90 mg/L, severe poisoning with con-
vulsions, hypotension resistant to parenteral infusion therapy,
and heart rhythm disorders 
1, 4.
Mesotherapy was discovered in Europe as a medical
and cosmetic method for intradermal injection of a mixture
of specific substances. Although traditionally used in the
treatment of pain, it has recently been used for cosmetic pur-
poses, especially in the treatment of cellulitis, as well as in
the local reduction of fatty deposits 
5. In these procedures,
the process of inhibition of phosphodiesterase contributes to
its overall lipolytic effect.
Case report
A 51-year old woman, underwent aesthetic treatment of
excess adipose tissue through lipolysis. The treatment took
about sixty minutes and was performed in a beauty salon,
under the control of a plastic surgeon specialist. It consisted
of 20 intradermal injections of caffeine solution. The patient
felt discomfort after the first two applications, and soon felt
ill with anxiety, nausea and the urge to vomit. Because of a
sudden disturbance of general condition, the patient was
further examined in the Emergency Center, Clinical Center
of Serbia, ascertaining suffering from somnolence and hy-
potension. Electrocardiographic (ECG) examination regis-
tered sinus rhythm and occasional nonsustained ventricular
tachycardia. Due to suspicion of underlying systemic toxic
effects during the treatment the patient was admitted to the
Poison Control Center, Military Medical Academy.
On admission the patient complained of nausea, vom-
iting, and chest palpitations. The patient was anxious, afeb-Volumen 69, Broj 8 VOJNOSANITETSKI PREGLED Strana 709
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rile, hyperventilating, with cold/moist skin, and mydriatic
pupils. The auscultatory findings in the lungs were normal.
The patient’s heart rate was 150 beats per min, tones cleares
without additional sounds. Blood pressure on admission was
130/80 mmHg. Injection marks on anterior abdominal wall
were present with surrounding hematomas (Figure 1). The
personal history of the patient indicated treatment of previ-
ous hypertension with nifedipine. ECG recorded paroxysmal
supraventricular tachycardia (PSVT) with the frequency of
146/min, changes in repolarization, ST segment depression
of 6 mm in left-sided leads (V4–V6) D1 and AVL (Figure 2).
Fig.1 – Injection marks on the anterior abdominal wall with
surrounding hematomas.
Biochemical analysis of the blood sodium level deter-
mined values of 147 mmol/L (normal range 135–147 mmol/L),
potassium 2.1 mmol/L (normal range 3.5 to 5.2 mmol/L), chlo-
ride 99 mmol/L (normal range 98–111 mmol/L), glucose 17
mmol/L (normal range 3.5 to 6.4 mmol/L), urea 5.6 mmol/L
(normal range 1.7 to 8.3 mmol/L), creatinine 69 mmol/L
(normal range 50–124 mmol/L), aspartate aminotransferase
(AST) 33 U/L (normal range 10–37 U/L), alanine amino-
transferase (ALT) 49 U/L (normal range 20–65 U/L), creat-
inine kinase (CK) 79 U/L (normal range 21–232 U/L). The
complete blood count showed elevated white blood cells
[(the first day of 22 u   10
9, a second day of 15.7 u 10
9 (nor-
mal range 4.00 to 10.8 u 10
9)], with normal values of red
blood cells, hemoglobin and platelets. Arterial blood gases
indicated acute respiratory alkalosis with a hypocapneic level
of carbon dioxide partial pressure (pCO2) 30.4 mmHg (nor-
mal range 32–48 mmHg), total pH 7.486 (normal range 7.35
to 7.45) and no underlying metabolic disorders.
Toxicology screening of the blood in the patient upon
admission confirmed the presence of caffeine in the concen-
tration of 85.03 mg/L (therapeutic cocentration of 1 to 10
mg/L (toxic being more than 25 mg/L) [using high perform-
ance liquid chromatography with ultraviolet scanning detec-
tion (HPLC-PDA)] and theophylline, 7.43 mg/L [therapeutic
concentration of 8 to 20 mg/L immuno-fluorescence polari-
zation method (AXYM)].
The patient was admitted to the intensive care unit with
continuous ECG monitoring and parenteral therapy. The first
6 h of parenteral therapy included 5 mg of verapamil, diaze-
pam 20 mg, 10 mg metoclopramide, infusion therapy with
3,000 mL of isotonic solution, and substitution with 100
mEq potassium chloride. Diuresis following this therapy was
an amount of 1,800 mL. In addition to the therapy, symp-
toms included heart rate slowing to 90/min, confirmed by
ECG finding (Figure 3), with repeated attack of PSVT at the
frequency of 170/min, which is the reason for inclusion of
beta blockers in the standard therapy.
On the second day of hospitalization the patient com-
plained of nausea, warranting removal of metocloperamide.
From that day until hospital discharge, the patients ECG
rhythm was at a normal frequency. Serum potassium level
was 2.3 mmol/L. Detection of blood caffeine levels of 57.73
mg/L and theophylline at a concentration 6.59 mg/L were
obtained.
On the third day, the patient complained of a headache,
as well as pains in the neck area. Hypertension was estab-
lished at 170/90 mmHg. Laboratory analysis determined hy-
pokalemia (serum potassium level 2.8 mmol/L). The con-
centration of caffeine in blood was 27.43 mg/L, which was
between the range of concentrations considered to be toxic.
The concentration of theophylline was 7.43 mg/L. The
Fig. 2 – The ECG on admission showed sinus rhythm, frequency of 146/min,
changes in repolarization, ST segment depression of 6 mm in left-sided leads
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treatment started with an angiotensin converting enzyme
(ACE) inhibitor, administered both parentally and orally, re-
sulting in correction of hypertension, as well as hypokalemia.
On the fourth day of hospitalization the patient was in
good condition and discharged. The ECG at discharge was
found to be a sinus rhythm, at the frequency of 67/min (Fig-
ure 4), with the signs of hypertrophy and left ventricular
overload. Normal values for biochemical parameters were
recorded. The concentration of caffeine in blood was 8.39
mg/L and 1.86 mg of theophylline/L, which was at the thera-
peutic level. On echocardiographic examination, there was
an enlarged left atrium of 4.3 cm, normal left ventricular di-
mensions, with concentric hypertrophy and a wall thickness
of 13 mm. There was no failure of segmental contractility;
ejection fraction was 65%. Diastolic function was altered by
delayed relaxation.
Discussion
Caffeine side effects and systemic toxicity in adults is
usually documented after oral administration, and during in-
travenous use in pediatric patients or neonates 
1.
Intravenous caffeine in neonates has been presented
with a number of severe toxic effects such as hypertension,
tachycardia, tachypnea, tremor, opisthotonus, tonic-clonic
convulsions, cardiac failure, pulmonary edema and metabolic
acidosis with confirmation of toxic concentrations of caf-
feine. The symptoms gradually retreated after 7 days, and the
concentration of caffeine was then between 60–70 mg/L 
6, 7.
Ingestion of large amounts of caffeine can cause significant
agitation, severe hypotension, tachycardia, ventricular ar-
rhythmia, cardiac arrest, myocardial infarction, hypokalemia,
rhabdomyolysis, seizures and acute renal impairment 
8, 9.
Waring et al. 
10 showed clinical data of 38 patients with caf-
feine ingested at an average dose of 1,040 mg (600 to 1,500
mg), which is equivalent to the amount found in about 10
cups of coffee. Out of them, 28 (73.7%) patients attempted
suicide by deliberate self-poisoning, 8 (21.1%) patients in-
gested caffeine in order to enjoy (energy drinks), and 2
(5.3%) patients did it for weight loss.
We reported acute poisoning caused by intradermal caf-
feine intake by intentional injections for aesthetic purpose.
So, that differs from accidental poisoning with caffeine,
usual entry of the toxin.
So far, it has not been proven that consuming caffeine
from coffee increases the risk of cardiovascular disease.
Also, there is no clear evidence that drinking moderate
amounts of coffee, 3 to 4 cups per day (about 300 to 400 mg
per day), poses a risk to health. However, certain groups of
people, including people with hypertension, children and
adolescents may be more sensitive to caffeine in terms of
Fig. 3 – The ECG after beginning the treatment showed heart rate slowing to 90/min
with changes in repolarization (the first day)
Fig. 4 – The ECG at discharge showed sinus rhythm, frequency of 80/min with signs of hypertrophy
and left ventricular overloadVolumen 69, Broj 8 VOJNOSANITETSKI PREGLED Strana 711
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side effects 
11. Before the treatment, the presented patient had
already had hypertension, but this higher risk to adverse ef-
fects of caffeine was not taken into account.
The contraindications to mesotherapy are 
12, 13: pregnant
and lactating females, insulin dependent diabetes mellitus,
history of bleeding disorders, history of strokes, history of
thromboembolic phenomena, patients on medication for car-
diac arrythmias, aspirin, warfarin, heparin, history of recent
cancer, severe heart disease, renal disease, any severe
chronic systemic disease.
The main clinical effects at both, caffeine therapeutic
doses as well as in case of poisonings with proven toxic con-
centrations, are from adenosine antagonism, beta adrenergic
receptor stimulation and phosphodiesterase inhibition. On
admission to the hospital, the presented patient’s ECG
showed repeated attacks of PSVT, with evidence of hyper-
tensive cardiomyopathy and hypoklemia.
Severe caffeine poisoning is relatively rare and accom-
panied by unwanted hemodynamic complications, including a
high mortality rate. Among complications are the most severe
forms of cardiac abnormalities: sinus tachycardia, ventricular
tachycardia and ventricular fibrillation, generalized convul-
sions, multiple organ failure (MOF) and cardiac arrest 
1, 8, 9, 14.
The presented patient was initially observed to have hypoten-
sion, nonsustained ventricular tachycardia, and PSVT, fortu-
nately with a favorable outcome. Sinus tachycardia is a com-
mon sign of poisoning, and is most likely benign in people
with no previous cardiac disease. However, sinus tachycardia
in methylxanthine poisoning, can progress to severe arrhyth-
mias. Atrial fibrillation, atrial flutter, multifocal atrial tachy-
cardia, ventricular tachycardia and ventricular fibrillation may
result from methylxanthine poisoning 
1. Caffeine stimulates
the respiratory center in the CNS, increasing the frequency of
breathing, causing hyperventilation, respiratory alkalosis, res-
piratory failure, respiratory arrest and acute lung injury (ALI).
On admission to the intensive care unit, arterial blood gas val-
ues described in the presented patient indicated respiratory al-
kalosis and hypocapnea, which was correlated with increased
respiration and tachypnea.
In the article of Scottish authors 
10, 24 (63.2%) patients
showed only gastrointestinal symptoms, nausea and vomit-
ing. In the first 6 hours of the treatment, the presented patient
showed gastrointestinal symptoms, nausea and vomiting,
which responded favorably to the use of metoclopramide.
It is known that caffeine causes psychiatric disorders
under certain circumstances. Caffeine, which is widely used
especially in younger population, is also found in many en-
ergy drinks, and can cause marked anxiety in otherwise
healthy individuals. This is particularly true in sensitive per-
sons with existing anxiety disorders. Caffeine may be associ-
ated with symptoms of depression, sleep disorders, and
worsening of psychotic disorders in people with schizophre-
nia
15. The presented patient was anxious upon admission,
and later complained of a headache. According to the Scot-
tish Poison Centre (for the period 2000 – 2008) dizziness,
headache, tremor and agitation were much less common
symptoms of caffeine poisoning in comparison to those with
gastrointestinal symptoms 
10.
Hypokalemia is a common manifestation of acute poi-
soning with methylxanthines resulting in beta adrenergic
agonism and stimulation of Na
+/K
+ ATP-ase, which leads
to a shift of potassium from the extracellular to intracellular
space. This can be accelerated by vomiting and loss of po-
tassium through the kidneys. In patients with theophylline
intoxication, hyperkalemia occurs early and is independent
of the initial laboratory analysis with vomiting 
16. The pre-
sented patient had a potassium concentration of 2.1
mmol/L, which was interpreted as a loss of potassium due
to vomiting. After the first analysis of toxic concentrations
of caffeine, hyperkalemia was interpreted as caffeine toxic
effect. We performed a parenteral and oral potassium re-
placement, which exhibited parallel falls in toxic concen-
trations of caffeine, but not to completely normal levels.
The concentration of caffeine in blood of the patient before
mezotherapy remains unknown, but there are recommenda-
tions that coffee or caffeine-containing beverages must not
be used for at least 12 h before the treatment 
17. In the pre-
sented patient, the concentration of caffeine was 85 mg/L
immediately after mezotherapy, and 57.73 mg/L on the
second day.
The immediate cause of death in severe caffeine poi-
soning is ventricular fibrillation, as has been shown by an
experimental work 
18. Generally speaking, a concentration of
caffeine in the blood of more than 100 mg/L is considered
lethal
19, 20.
A case of sudden death has been documented involving
a 25-year-old woman previously diagnosed with mitral valve
prolapse. Cardiac arrest occurred immediately after drinking
energy beverage. At autopsy screening, the presence of 19
mg/L caffeine was indicated in the aortic blood. The caffeine
concentration was 10 g/L 
21 upon further analysis. Swedish
forensic experts during a year period witnessed four fatali-
ties, demonstrating caffeine concentration of 80 to 100
mg/L 
22 in post-mortem toxicological analysis.
Fatal caffeine overdose in adults is rare and involves
more than 5 g of a drug containing caffeine to cause death.
American toxicologists 
23 from New Mexico, during a one
year follow-up documented accidental caffeine poisoning as
a cause of death in two patients: in a 39-year-old woman
with the history of intravenous drug abuse with the caffeine
concentration 192 mg/L in femoral blood and in a 29-year-
old man with the disease history of obesity and diabetes
mellitus, with caffeine concentration of 567 mg/L in femoral
blood.
In both patients, the cause of death was accidental caf-
feine poisoning. At the begining of the 80’s, articles were
published about the cosmetic application of  phosphodiester-
ase inhibitors and cAMP in the treatment of lipodystrophy 
5.
In animal models, after subcutaneous application, the effi-
cacy of methylxanthines themselves was tested, usually in-
corporating caffeine and theophylline, methylxanthines, or in
combination with other substances that have a lipolytic ef-
fect. Their effect on the rate of absorption was monitored in
accordance with artificially induced granulomas in adipose
tissue. A better effect was achieved by combining prepara-
tions
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Adverse effects of cosmetic treatments for cellulitis oc-
cur with intradermal injection of lipolytic substances, and
can be presented as pain and erythema at the puncture site,
vagal reactions, injury to nerves and blood vessels, skin ne-
crosis and hematoma formation. Hematomas, which should
not follow this type of treatment, are usually the most com-
mon side effect, and are a consequence of the effects of the
applied substances interfering with the process of coagula-
tion. According to the previously published data there are
numerous local side effects associated with therapy 
5. Ab-
dominal wall hematomas in the presented patient are shown
as local side effects caused by substances in deeply applied
injection (Figure 3). After application there was a massive
absorption into the circulation as proved by the elevated con-
centration of caffeine 85.03 mg/L in the blood.
The most common local complications of mesotherapy
are as follows: bruising and edema due to the chemicals used
in mesotherapy 
13, 24, skin necrosis 
25–27, atypical mycobacte-
rial infections 
28, allergic reactions due to various chemi-
cals
26, 29, atrophy and lipodystrophy 
25, postinflammatory
hyperpigmentation nodularity 
25, after irregular lipolysis 
29
etc.
Few papers describe systemic toxicity of substances ap-
plied during and after mesotherapy. Brazilian authors 
30 de-
scribe the first case of systemic toxicity in a young woman
presenting with thyrotoxicosis caused by mesotherapy with
triiodthyroacetate acid. Alster and Tanzi 
31 reported that in
2003, mesotherapy was banned by the Brazilian National
Agency of Health due to its unwanted side effects. There are
also systemic complications. “Systemic complications are
allergic reactions, vagal syndromes, lipothymia, infections
(HIV, hepatitis, etc) and liver toxicity with demyelination of
nerves due to large doses of phosphatidylcholine” 
24, 25.
In addition to supportive and symptomatic treatment for
severe poisoning and systemic toxic effects, hemoperfusion
and hemodialysis are strongly recommended 
14, 32. Fortunately,
the presented female patient responded favorably to the treat-
ment and did not require the action of extracorporeal detoxifi-
cation. Cardiopulmonary resuscitation was needed in the worst
case scenario. There were documented cases of survival in pa-
tients with cardiotoxicity induced by caffeine in which cardio-
pulmonary support was applied percutaneously 
9.
Conclusion
The severe systemic toxic effects of caffeine applied
intradermally in mesotherapy were seen in the presented pa-
tient. The cause of massive caffeine absorption from the sub-
cutaneous tissue into the systemic circulation of the patient
was partly due to the tiny blood vessels in the skin, as indi-
cated by hematomas in the abdominal wall. The clinical pic-
ture showed mild gastrointestinal symptoms (nausea, vomit-
ing), CNS disorders (somnolence, anxiety), and cardiovas-
cular disturbances (hypotension, ventricular tachycardia and
nonsustained PSVT). In this era of increasing popularity of
mesotherapeutic aesthetic treatment, one should keep in
mind the possibility of a significant absorption of the applied
substances into circulation and their potential systemic side
effects. Proper methods of intervention need to be applied in
specialized institutions for cosmetic surgery that are staffed
and equipped to respond in case of complications, as well as
in poisonings.
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